Sandip P. Patel, MD, discusses novel targets in non-small cell lung cancer.
Sandip P. Patel, MD, Associate Professor, University of California, San Diego (UCSD), Co-lead, Experimental Therapeutics, Assistant Director, San Diego Center for Precision Immunotherapy, Director, Clinical Trials Office, UCSD Moores Cancer Center, UCSD Health Science, discusses new targets in non-small cell lung cancer (NSCLC).
Research in the NSCLC is generating significant enthusiasm for new targets, Patel says. Certain investigative targets, such as NRG1 fusions, are based on mRNA and are therefore best detected via RNA tests. Additional KRAS inhibitors directed to the pan-KRAS modifications or KRAS G12D mutations could change the paradigm in the NSCLC, Patel says. New immunotherapies, such as those directed against TIGIT, as well as cell therapies are also in development and could emerge for certain patient populations, Patel explains.
However, practice change efforts in the NSCLC have recently been localized to the early stages, Patel says. For example, on October 15, 2021, the FDA approved aezolizumab (Tecentriq) for use as an adjuvant treatment after resection and platinum-based chemotherapy in patients with stage II to IIIA NSCLC whose tumors express PD- L1 of 1% or more with SP263. trial. Additionally, neoadjuvant nivolumab (Opdivo) in combination with chemotherapy improved the rate of pathologic complete response compared to chemotherapy alone in patients with resectable NSCLC, suggesting that this regimen may be a potential treatment option for patients. .
Obtaining molecular test results prior to treatment selection is essential to optimize targeted options, Patel concludes.